SOLID BIOSCIENCES INC
Solid Biosciences Inc (ticker: SLDB) is a clinical-stage biotechnology company focused on developing gene therapy and other treatments for Duchenne muscular dystrophy (DMD), a severe neuromuscular disorder. The company’s work centres on delivering genetic payloads to address the underlying causes of DMD, but like many early-stage biotech firms, it has faced clinical and regulatory challenges that have contributed to share-price volatility. With a market capitalisation of about $467.99M, Solid Biosciences has limited or no commercial revenues and depends on successful clinical trials, regulatory approvals and potential partnerships or financing to progress. Investing in SLDB can offer exposure to high-reward science, yet carries material risks — clinical setbacks, manufacturing hurdles and dilution from fundraising are common. This summary is for educational purposes only and not personalised advice; investors should research the latest trial data, regulatory filings and the company’s financial position before considering any investment and be prepared for significant price swings and the possibility of losing capital.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Solid Biosciences' stock with a target price of $16.22, indicating strong growth potential.
Financial Health
Solid Biosciences is generating strong cash flow and has a good book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SLDB
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Gene therapy focus
The company targets the genetic root of Duchenne muscular dystrophy, a high-potential scientific approach — though clinical and safety hurdles can be significant.
Volatility and catalysts
Trial readouts, regulatory updates and financing moves are likely to drive price swings; these events can create both opportunities and sharp downside risks.
Market and funding needs
As a development-stage firm with limited revenues, progression depends on capital, partnerships and regulatory approvals — investors should assess funding plans carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
